Genetic testing identified a somatic JAK2 V617F mutation (allelic frequency of 17%), consistent with essential thrombocythemia; no other mutations were detected, including no detectable BCR::ABL1 gene. This evidence concerns the gene BCR and essential thrombocythemia.